Clinical Characteristics of Anti-aquaporin 4 Antibody Positive Optic Neuritis in Japan

References

• Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106–2112. doi:10.1016/S0140-6736(04)17551-X.
   PubMed Web of Science ®Google Scholar
• Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473–477. doi:10.1084/jem.20050304.
   PubMed Web of Science ®Google Scholar
• Lucchinetti CF, Guo Y, Popescu BF, Fujihara K, Itoyama Y, Misu T. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol. 2014;24:83–97. doi:10.1111/bpa.12099.
   PubMed Web of Science ®Google Scholar
• Fujihara K. Neuromyelitis optica and astrocytic damage in its pathogenesis. J Neurol Sci. 2011;306:183–187. doi:10.1016/j.jns.2011.02.018.
   PubMed Web of Science ®Google Scholar
• Takagi M, Tanaka K, Suzuki T, Miki A, Nishizawa M, Abe H. Anti-aquaporin-4-antibody-positive optic neuritis. Acta Ophthalmol. 2009;87:562–566. doi:10.1111/j.1755-3768.2008.01259.x.
   PubMed Web of Science ®Google Scholar
• Nakao Y, Yamamoto H, Arimura E, et al. Clinical features of anti-aquaporin 4 antibody-positive optic neuritis in Japanese. Shinkei Ganka. 2008;25:327–342.
   Google Scholar
• Trebst C, Jarius S, Berthele A, et al. Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261:1–16. doi:10.1007/s00415-013-7161-2.
   PubMed Web of Science ®Google Scholar
• Kowarik MC, Soltys J, Bennett JL. The treatment of neuromyelitis optica. J Neuroophthalmol. 2014;34:70–82. doi:10.1097/WNO.0000000000000102.
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim W, Huh SY, Lee KY, Jung IJ, Kim HJ. Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels. J Clin Neurol. 2013;9:36–42. doi:10.3988/jcn.2013.9.1.36.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Nakashima I, Misu T, Miyazawa I, Shiga Y, Fujihara K, Itoyama Y. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler. 2007;13:128–132. doi:10.1177/1352458506071174.
   PubMed Web of Science ®Google Scholar
• Bonnan M, Cabre P. Plasma exchange in severe attacks of neuromyelitis optica. Mult Scler Int. 2012;2012:787630.
   PubMedGoogle Scholar
• Bonnan M, Valentino R, Olindo S, Mehdaoui H, Smadja D, Cabre P. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler. 2009;15:487–492. doi:10.1177/1352458508100837.
   PubMed Web of Science ®Google Scholar
• Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology. 2002;58:143–146.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, Watanabe S, Shiga Y, Kanaoka C, Fujimori J, Sato S, Itoyama Y. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain. 2007;130:1235–1243. doi:10.1093/brain/awm062.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Tani T, Tanaka M, et al. Anti-aquaporin 4 antibody in selected Japanese multiple sclerosis patients with long spinal cord lesions. Mult Scler. 2007;13:850–855. doi:10.1177/1352458507076976.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Banwell B, Bennett JL, et al. International panel for NMO diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–189. doi:10.1212/WNL.0000000000001729.
   PubMed Web of Science ®Google Scholar
• Kitley J, Leite MI, Nakashima I, Waters P, McNeillis B, Brown R, Takai Y, Takahashi T, Misu T, Elsone L, Woodhall M, George J, Boggild M, Vincent A, Jacob A, Fujihara K, Palace J. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012;135:1834–1849. doi:10.1093/brain/aws109.
   PubMed Web of Science ®Google Scholar
• Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation. 2012;9:14. doi:10.1186/1742-2094-9-14.
   PubMed Web of Science ®Google Scholar
• Nagaishi A, Takagi M, Umemura A, Tanaka M, Kitagawa Y, Matsui M, Nishizawa M, Sakimura K, Tanaka K. Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes. J Neurol Neurosurg Psychiatry. 2011;82:1360–1364. doi:10.1136/jnnp-2011-300403.
   PubMed Web of Science ®Google Scholar
• Lai C, Tian G, Takahashi T, Liu W, Yang L, Zhang X. Neuromyelitis optica antibodies in patients with severe optic neuritis in China. J Neuroophthalmol. 2011;31:16–19. doi:10.1097/WNO.0b013e3181f8a693.
   PubMed Web of Science ®Google Scholar
• Brody J, Hellmann MA, Marignier R, Lotan I, Stiebel-Kalish H. Neuromyelitis optica spectrum disorder: disease course and long-term visual outcome. J Neuroophthalmol. 2016;36:356–362. doi:10.1097/WNO.0000000000000403.
   PubMed Web of Science ®Google Scholar
• Yamagami A. Investigation of the visual field defects pattern of anti-aquaporin 4 antibody optic neuriti. Shinkei Ganka. 2015;32:135–141.
   Google Scholar
• Bennett JL, de Seze J, Lana-Peixoto M, Palace J, Waldman A, Schippling S. Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography. Mult Scler. 2015;21:678–688. doi:10.1177/1352458514567216.
   PubMed Web of Science ®Google Scholar
• Khanna S, Sharma A, Huecker J, Gordon M, Naismith RT, Van Stavern GP. Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica multiple sclerosis. J Neuroophthalmol. 2012;32:216–220. doi:10.1097/WNO.0b013e318254c62d.
   PubMed Web of Science ®Google Scholar
• Merle H, Olindo S, Jeannin S, Valentino R, Mehdaoui H, Cabot F, Donnio A, Hage R, Richer R, Smadja D, Cabre P. Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol. 2012;130:858–862. doi:10.1001/archophthalmol.2012.1126.
   PubMedGoogle Scholar
• Feasby T, Banwell B, Benstead T, Bril V, Brouwers M, Freedman M, Hahn A, Hume H, Freedman J, Pi D, Wadsworth L. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev. 2007;21:S57–107. doi:10.1016/j.tmrv.2007.01.002.
   PubMed Web of Science ®Google Scholar
• Nakao Y, Nakamura Y, Aomatsu K, Hirano M, Sakaoto H. Intravenous immunoglobulin treatment in corticosteroid refractory anti-aquaporin 4 antibody-seropositive optic neuritis. Shinkei Ganka. 2012;29:424–433.
   Google Scholar
• Watanabe S, Misu T, Miyazawa I, Nakashima I, Shiga Y, Fujihara K, Itoyama Y. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler. 2007;13:968–974. doi:10.1177/1352458507077189.
   PubMed Web of Science ®Google Scholar
• Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, Mandrekar J, Thapa P, McKeon A. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology. 2011;77:659–666. doi:10.1212/WNL.0b013e31822a2780.
   PubMed Web of Science ®Google Scholar
• Elsone L, Kitley J, Luppe S, et al. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scle. 2014;20:1533–1540. doi:10.1177/1352458514525870.
   PubMed Web of Science ®Google Scholar
• Kitley J, Elsone L, George J, Waters P, Woodhall M, Vincent A, Jacob A, Leite MI, Palace J. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry. 2013;84:918–921. doi:10.1136/jnnp-2012-304774.
   PubMed Web of Science ®Google Scholar
• Ramanathan RS, Malhotra K, Scott T. Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate. BMC Neurol. 2014;14:51. doi:10.1186/s12883-014-0196-x.
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim W, Park MS, Sohn EH, Li XF, Kim HJ. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol. 2011;68:473–479. doi:10.1001/archneurol.2010.322.
   PubMedGoogle Scholar
• Weinstock-Guttman B, Ramanathan M, Lincoff N, Napoli SQ, Sharma J, Feichter J, Bakshi R. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol. 2006;63:957–963. doi:10.1001/archneur.63.7.957.
   PubMedGoogle Scholar
• Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013;70:1110–1117. doi:10.1001/jamaneurol.2013.3071.
   PubMed Web of Science ®Google Scholar
• Greenberg BM, Graves D, Remington G, Hardeman P, Mann M, Karandikar N, Stuve O, Monson N, Frohman E. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler. 2012;18:1022–1026. doi:10.1177/1352458511432896.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, O'Toole O, Wingerchuk DM. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013;12:554–562. doi:10.1016/S1474-4422(13)70076-0.
   PubMed Web of Science ®Google Scholar
• Zheng X, Zhang X, Liu X, Mu W, Yang W, Liu Y, Ge P, Li H. Patient with neuromyelitis optica spectrum disorder combined with Sjögren’s syndrome relapse free following tacrolimus treatment. Intern Med. 2014;53:2377–2380.
   PubMed Web of Science ®Google Scholar
• Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, Carter J, Keegan BM, Kantarci OH, Pittock SJ. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009;66:1128–1133. doi:10.1001/archneurol.2009.175.
   PubMedGoogle Scholar